



UTILITY CONTINUATION PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.: 4152-1-PUS-9
Inventors: George N. Cox, III of 907 Pikes Peak Lane, Louisville, Colorado 80027
Express Mail Label No.: **EL975241398US**
Title: "CYSTEINE VARIANTS OF ERYTHROPOIETIN"
Group Art Unit: 1648
Examiner: Lucas, Z.



Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This is a Continuation application of pending prior application No. 10/400,377, filed March 26, 2003. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference.

Enclosed for filing with the above-identified utility patent application are the following:

1. Applicant claims small entity status. See 37 CFR 1.27.
2. Copy of Oath/Declaration and specification from the above-referenced pending prior application (37 CFR 1.63(d))
3. Information Disclosure Statement (IDS/PTO-1449)
4. Copies of IDS Citations (Number of References: 1)
5. Preliminary Amendment
6. Declaration of Angela Dallas Sebor
7. Return Postcard (MPEP 503) *(should be specifically itemized)*
8. A check in the amount of \$611.00 is enclosed.

FEE CALCULATION:

Cancel in this application original Claims 1-23 of the prior application before calculating the filing fee.

	(COL. 1) NO. FILED			(COL. 2*) NO. EXTRA	SMALL ENTITY			LARGE ENTITY	
					RATE	FEE		RATE	FEE
BASIC FEE:						\$385.00	OR		\$770.00
TOTAL CLAIMS:	29	-	20	9	X \$9 =	\$81.00	OR	X \$18 =	
INDEP. CLAIMS:	3	-	3	0	X \$43 =	\$0.00	OR	X \$86 =	
MULTIPLE DEPENDENT CLAIMS					+ \$145 =	\$145.00	OR	+ \$290 =	
*IF THE DIFFERENCE IN COL. 2 IS LESS THAN ZERO, ENTER "0" IN COL. 2.					TOTAL:	\$611.00			

OTHER INFORMATION:

1. The Commissioner is hereby authorized to debit any underpayments or credit any overpayment to Deposit Account No. 19-1970.
2. The Commissioner is hereby authorized to charge all required fees for extensions of time under §1.17 to Deposit Account No. 19-1970.
3. The Power of Attorney appears in the original papers of the prior pending application.
4. The prior application is assigned to Bolder Biotechnology, Inc.


5. Correspondence Address:

Angela Dallas Sebor
SHERIDAN ROSS P.C.
1560 Broadway, Suite 1200
Denver, Colorado 80202-5141
Telephone: (303) 863-9700
Facsimile: (303) 863-0223

Customer No: **22442**

Respectfully submitted,

SHERIDAN ROSS P.C.



Angela Dallas Sebor
Registration No. 42,460

Date: February 5, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:

COX

Serial No.: Not Yet Assigned

Filed: February 5, 2004

Atty. File No.: 4152-1-PUS-9

For: "CYSTEINE VARIANTS OF
ERYTHROPOIETIN"
(as amended)

) Group Art Unit:
)

) Examiner:
)

) DECLARATION OF
) ANGELA DALLAS SEBOR
)

) **EXPRESS MAIL: EL975241398US**
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Angela Dallas Sebor, am a Patent Agent and represent Applicant in the above-identified patent application. I hereby confirm that the amendatory material amended into the specification in the Preliminary Amendment filed on this date consists of the same material incorporated by reference in the referencing application.

Specifically, the description of the amino acid positions of the regions of erythropoietin that are added to the above-identified specification are the amino acid positions, using the position numbers relative to SEQ ID NO:2 of the above-identified specification, that are disclosed for these regions in Fig. 1B on page 15986 of Boissel et al., *Journal of Biological Chemistry*, v. 268, p15983-15993, 1993.

I hereby declare that all statements made herein of my own are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the subject application or any patent issuing therefrom.

Date: February 5, 2004 By: Angela Sebor
Angela Dallas Sebor